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Abstract
Introduction. Gastric outlet obstruction (GOO) is a frequent feature of advanced pancreatic carcinoma. Self-expandable
metal stents (SEMS) allow the condition to be managed outside by endoscopy rather than surgical bypass. The aim of this
study is to report our experience in a district general hospital with SEMS for palliation of pancreatic carcinoma-related
GOO. Patients and methods. All patients admitted with or developing GOO secondary to pancreatic adenocarcinoma
between January 2004 and December 2005 were identified. Notes were retrieved to determine the efficacy of stenting
including: complications of the procedure, length of stay, readmissions and long-term patency. Results. Of 39 new cases of
pancreatic cancer, 9 patients presented with (n6) or developed (n3) duodenal obstruction. In one patient, previous
gastric surgery restricted access. Stenting was attempted in 8 patients (4 M and 4 F) with a mean age of 63 years (range 42
76 years). In one case, the duodenal invasion was too extensive to allow passage of the guide-wire and open bypass was
performed. Stenting was successful in the remaining seven patients with no early complications. The median hospital stay
post-procedure was 7 days (range 511 days). One patient was re-admitted after 11 weeks with recurrent duodenal
obstruction and a second stent was placed. The median survival post-stenting was 10 weeks (range 328 weeks).
Conclusions. SEMS allows patients to leave hospital quickly and return to daily activities, albeit for the short term. The
procedure requires an experienced interventional endoscopist but can be accomplished safely in the DGH setting.
Introduction
Pancreatic adenocarcinoma, while only the 10th most
common carcinoma, is the fourth leading cause of
cancer-related mortality [1]. The reason for the high
mortality is the fact that the majority of patients, up to
85%, present with advanced disease and tumours that
are unresectable due to the presence of local invasion
or metastases [2]. Around 90% of patients with
pancreatic adenocarcinoma will develop jaundice [3]
and there is considerable evidence that endoscopically
placed self-expanding metallic stents (SEMS) are
effective in relieving jaundice in patients with inoper-
able tumours [47]. In combination with gemcita-
bine-based and oxaliplatin-based regimens [8], a
median survival of 11 months may now be achieved
for those with locally advanced disease [9].
Gastric outlet obstruction (GOO) secondary to
duodenal invasion is usually a late manifestation of
pancreatic carcinoma and occurs in up to 20% of
patients [10]. The traditional approach to GOO
associated with pancreatic adenocarcinoma has been
surgical bypass by means of gastroenterostomy. The
use of duodenal SEMS for GOO was first reported for
an advanced gastric carcinoma in 1992 [11]. Since
this time, evidence has accumulated that this method
of maintaining duodenal patency may also be of value
in pancreatic adenocarcinoma and there are now
several large series (25 with pancreatic cancer)
[9,12,13] and indeed a few small randomized con-
trolled trials from large centres supporting this
management option [14,15].
In the United Kingdom, reconfiguration of cancer
services has led to the centralization of services for the
resection of pancreatic cancer, with a recommended
catchment population of at least 2 million for a
pancreatic team [16]. However, it is unclear where
patients with pancreatic carcinoma who are not
candidates for surgery should be managed.
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The aim of this study was to review the experience
of a district general hospital with the management of
duodenal obstruction secondary to pancreatic carci-
noma to determine whether GOO could be managed
effectively by means of SEMS.
Patients and methods
All new cases of histologically confirmed pancreatic
adenocarcinoma diagnosed during the period January
2004 to December 2005 were identified from the
prospectively maintained pathology department data-
base. Patient notes were retrieved and reviewed to
determine those patients with advanced pancreatic
carcinoma who either presented with or developed
gastroduodenal obstruction during their period of
palliation. This cohort formed the study population.
For this subgroup, patient demographics were
collected and details of the nature of the obstruction
were noted. The efficacy of subsequent management
using SEMS, including success in deployment and the
development of early stent-related complications, was
recorded. In addition, the presence of a biliary stent at
the time of duodenal stenting was noted, as was the
subsequent need for biliary stenting.
Details of the length of post-procedure hospital stay
were noted, as was the need for readmission for stent
and non-stent-related complications. The long-term
patency and requirements for further information
were recorded, as was patient survival.
Results
During the 2-year period covered by the study, 39
new cases of biopsy-confirmed pancreatic adenocar-
cinoma were diagnosed and discussed within the
context of a multidisciplinary team setting. Thirty-
six of the patients presented (n32) with or devel-
oped (n4) jaundice during the course of their
disease.
Nine patients presented with (n6) or subse-
quently developed (n3) duodenal obstruction. Pa-
tients within this cohort had stage III (n4) or stage
IV (n5) disease and were thus unsuitable for
resection.
All patients with duodenal obstruction reported
unremitting vomiting and were unable to tolerate any
form of diet. In the cases in which a diagnosis of
pancreatic cancer had previously been established, the
diagnosis of duodenal obstruction was confirmed by
endoscopy and a contrast study was performed to
determine the length of the stricture and suitability for
stenting. In the remaining patients, in addition to the
investigations detailed, a computed tomography (CT)
scan was also performed for staging of the tumour.
In one patient, a previous partial gastrectomy
prevented access to the duodenum and stenting was
not attempted. Of 8 patients in whom stenting was
attempted, there were 4 males and 4 females with a
mean age 63 years (range 4276 years). In one case
the duodenal invasion was too extensive to allow
passage of the guide-wire and the patient underwent
open bypass; stenting was thus successful in 7 of 8
cases. No early stent-related complications, such as
bleeding or perforation, were encountered and all
patients subsequently managed to tolerate diet. A
biliary stent was present in three cases at the time of
duodenal stenting and a stent was inserted as a
combination procedure in a further four cases.
Figure 1 illustrates the radiological appearance of a
deployed duodenal stent and Figure 2 demonstrates
its endoscopic appearance.
The median hospital stay post-procedure was 7
days (range 511 days) and all patients left hospital
able to tolerate a solid diet. One patient was re-
admitted after 11 weeks with recurrent duodenal
obstruction and a second stent was placed. A further
patient who was initially not jaundiced became icteric
and required a biliary stent. This was successfully
inserted endoscopically. There were no further hospi-
tal admissions and the patients were palliated in the
community. In five cases a referral was made to an
oncologist for consideration of chemotherapy post-
stenting, but this was only instituted in two cases due
to patient co-morbidity. The median survival post-
stenting was 10 weeks (range 328 weeks).
Discussion
This series, while relatively small, was accumulated in
only 2 years and confirms the experience of tertiary
care facilities in demonstrating the benefit of duode-
nal stenting of patients with advanced pancreatic
malignancy. Stenting was successful in 7 of 8 patients
in whom it was attempted and in all but one of the
Figure 1. Position of deployed duodenal stent as seen on radi-
ological imaging.
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patients with duodenal obstruction. The results in
terms of efficacy are comparable to the existing
literature, where success rates of 92100% have
been reported [9,1215]. There were no significant
complications related to the stenting procedure in this
series, although it must be acknowledged that these
do exist and have been documented with a varying
prevalence from 0 to 56% of cases [9,1215,17].
Significant complications in centres with a large
experience include stent migration (06%), duodenal
perforation (03%), cholangitis (06%) and death
(01.4%) [9,1215].
Stent occlusion by tumour, which is more a
function of the disease than a complication, has
been reported in 1021% and this may be treated by
insertion of additional stents, such as in our series
[9,1215]. One of our cases, who did not have a
biliary stent placed at the time of duodenal stenting,
subsequently developed jaundice and had his biliary
tree successfully stented. This was early in our
experience and we would now advocate prophylactic
stenting of the biliary tree even in the absence of
jaundice, as biliary obstruction is likely during the
course of the disease. This approach has also been
advocated by Maire and colleagues, who noted the
technical difficulties in accessing the bile duct in the
presence of a duodenal stent [9].
The median survival in this cohort was a rather
disappointing 10 weeks and reflects the aggressive
nature of advanced pancreatic carcinoma. While there
are encouraging early reports from studies of gemci-
tabine and oxaliplatin, the population with duodenal
obstruction have significantly more advanced disease
than those simply with bile duct invasion. In reviewing
the paper by Louvet and colleagues, it is evident that
there is no specific mention of patients with duodenal
invasion, and these patients if part of their cohort,
have simply been included in the main analysis [8]. In
the current series, the short hospital stay was a
significant benefit, and only two patients required
re-admission for duodenal stent or disease-related
problems. In both cases, there was only a short in-
hospital stay and palliation was continued in the
community. The re-intervention rate is also compar-
able to data produced by larger centres.
Compared to the large published series and trials
[9,1215], and indeed earlier case series, which were
all at large tertiary referral centres, this paper reports
the experience of a district general hospital, where a
skilled endoscopist was able to perform these ad-
vanced interventional techniques with comparable
efficacy, and thus confirms wider potential application
duodenal stents. Indeed, we have used stents for
gastric (n1), colonic (n1), cholangiocarcinoma
(n1) and small-bowel adenocarcinoma (n1) with
similar results.
In a previous unpublished audit of patients pre-
senting with pancreatic carcinoma from 19962002 at
our institution, 134 patients were identified, 17 of
them respectable; 74 exhibited advanced disease and
43 were assessed as being unfit for major surgery.
Thus, 117 patients would be managed locally by
means of insertion of biliary stents as the majority will
present with jaundice. In this cohort of patients, those
with GOO underwent surgical bypass and morbidity
was high.
Maetani and colleagues retrospectively compared
stenting and gastrojejunostomy and demonstrated a
reduced time to oral intake at 1 versus 9 days, and also
improved performance status [18]. Fiori et al., in
addition to noting an earlier intake, also noted a
significantly shorter hospital stay in their small rando-
mized trial [15]. A recent meta-analysis of stenting
versus gastroenterostomy found in favour of stenting in
terms of: a higher clinical success rate, shorter interval
to diet, a lower incidence of delayed gastric empting
and a shorter hospital stay [19]. Similarly, Siddiqui
et al., in a decision analysis of stenting versus surgery
(open and laparoscopic) in the management of malig-
nant gastroduodenal obstruction, found stenting to be
superior both clinically (lower mortality) and econom-
ically (more cost-effective) [20].
There is evidence from several large studies that
centralization of pancreatic cancer resectional services
improves results, with better results achieved by
centres with higher workloads [21,22]. However, only
a small percentage of patients will be candidates for
resection. The current system in the United Kingdom
does not have the capacity for all patients with
pancreatic cancer to be seen and arranged in these
tertiary centres, and so the majority of patients will
continue to be managed in peripheral centres. While
the benefits of biliary stenting are well established
for the management of jaundice in pancreatic malig-
nancies, this study has demonstrated that duodenal
Figure 2. Endoscopic appearance of deployed duodenal stent.
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stenting can be performed safely and effectively in
peripheral units. This procedure has improved the
quality of palliative care in terms of minimizing hospital
stay and allowing a quick return to dietary intake, but
also saves a patient with advanced disease the incon-
venience of travelling to a tertiary centre for palliative
treatment.
Conclusions
In patients with a severely restricted life expectancy,
endoscopic duodenal stenting allows individuals to
leave hospital quickly and return to daily activities,
albeit for the short term. The procedure requires an
experienced interventional endoscopist but can be
accomplished in the district general hospital setting,
and patients do not have to be referred to a tertiary
centre.
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